维持性阿奇霉素能否减少哮喘急性发作?个体参与者数据荟萃分析
该系统综述与个体参与者数据荟萃分析检索至2019年2月,纳入3项平行组双盲随机对照试验(n=604),比较成人至少8周阿奇霉素与安慰剂,评估至少6个月的急性发作。结果显示阿奇霉素与哮喘及非嗜酸性、嗜酸性和重症哮喘亚组的急性发作率降低相关,且耐受性良好。
要点
- 阿奇霉素维持治疗可降低哮喘患者急性发作率。
- 嗜酸性哮喘患者口服糖皮质激素疗程减少。
- 非嗜酸性和重症哮喘患者抗生素疗程减少。
核心结论
- 维持性使用阿奇霉素可减少嗜酸性、非嗜酸性和重症哮喘患者的急性发作。
研究设计与样本
- 系统检索Embase、MEDLINE、PubMed、Cochrane Library、ClinicalTrials.gov及既往系统综述参考文献,检索时间至2019年2月。
- 纳入标准为平行组、双盲、随机对照试验,成人比较至少8周阿奇霉素与安慰剂,急性发作结局评估至少6个月。
- 共纳入3项研究,样本量n=604。
- 采用个体参与者数据荟萃分析评估主要结局急性发作,次要结局采用随机效应荟萃分析。
主要发现
- 个体参与者数据荟萃分析中,阿奇霉素治疗与哮喘总体及非嗜酸性、嗜酸性和重症哮喘亚组的急性发作率降低相关(急性发作定义为因哮喘恶化口服糖皮质激素疗程、下呼吸道感染抗生素使用、住院和/或急诊就诊)。
- 分别分析各急性发作类型时,嗜酸性哮喘患者报告更少的口服糖皮质激素疗程,非嗜酸性和重症哮喘患者报告更少的抗生素疗程。
- 阿奇霉素耐受性良好。
临床怎么用
- 对于嗜酸性、非嗜酸性和重症哮喘患者,可考虑维持性阿奇霉素治疗以减少急性发作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preventing exacerbations is an important goal of asthma treatment. Long-term treatment with azithromycin may help achieve this. Our aim was to conduct a systematic review and individual participant data (IPD) meta-analysis to examine the efficacy of azithromycin in reducing exacerbations in asthma, and in the subphenotypes of noneosinophilic asthma, eosinophilic asthma and severe asthma. METHOD: We completed a systematic search of Embase, MEDLINE, PubMed, Cochrane Library, ClinicalTrials.gov and reference lists of previous systematic reviews in February 2019. We included parallel-group, double-blind, randomised controlled trials in adults comparing at least 8 weeks of azithromycin treatment with placebo, where the outcome of exacerbations was assessed over at least 6 months. Data were extracted from published sources, Cochrane Risk of Bias Tool was applied and IPD were sought from authors. Reviews were undertaken in duplicate. We conducted an IPD meta-analysis on the primary outcome of exacerbations and a random effects meta-analysis for secondary outcomes. RESULTS: Three studies were identified (n=604). In the IPD meta-analysis, treatment with azithromycin was associated with a reduced rate of exacerbations (oral corticosteroid course due to worsening asthma, antibiotic use for lower respiratory tract infection, hospitalisation and/or emergency department visits) in asthma as well as in the noneosinophilic, eosinophilic and severe asthma subgroups. Examining each exacerbation type separately, patients with eosinophilic asthma reported fewer oral corticosteroid courses, and patients with noneosinophilic and severe asthma reported fewer antibiotic courses. Azithromycin was well tolerated. DISCUSSION: Maintenance use of azithromycin reduces exacerbations in patients with eosinophilic, noneosinophilic and severe asthma.
引用
- Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J. 2019. PMID: 31515407. doi:10.1183/13993003.01381-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。